Home
ViGenCell

ViGenCell Market Share Analysis for June 2026

Health > Medicine

Domainvigencell.com

Year Founded2013

Employees51 - 200

Annual Revenue--

ViGenCell

ViGenCell (including company regionals)

vigencell.com

See more website traffic and engagement information

Total visits to ViGenCell's top domains

Understand ViGenCell market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

vigencell.com11.4K

See more with Sales Intelligence

Avg. visit duration in ViGenCell's top domains

Analyze ViGenCell engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

vigencell.com00:00:27

See more with Sales Intelligence

Avg. pageviews on ViGenCell's top domains

See how ViGenCell keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

vigencell.com2.70

See more with Sales Intelligence

ViGenCell top competitors by domain

Top similar sites in June 2026, ranked by their affinity

kuraoncology.comCompany NameKura OncologyEmployees51 - 200HQUnited States, California, San DiegoAnnual revenue$25M - $50MTotal visits16.8KHealth > Biotechnology and Pharmaceuticals

Top technologies used by ViGenCell

These are the website technologies, by industry, used by ViGenCell top domains

Advertising (1)

PubMatic

Audio Video Media (1)

YouTube

Mobile (1)

Meta Viewport

Other (1)

Google API

More Technologies

1

See all

News & Signals from ViGenCell

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVigencell is developing cell therapy programs based on EiNK platform generation on Apr 21st '26.In addition, ViGenCell is developing next-generation cell therapy programs based on its EiNK(TM) platform in collaboration with Therabest, including 'VC302' for glioblastoma and 'VC420' for hepatocellular carcinoma, both currently in preclinical development.

NewsVigencell went public on Jul 1st '21.ViGenCell, an innovative biotech firm in which Boryung Pharmaceutical holds a 29.5 percent stake, is on track to make an initial public offering in July.